Cargando…
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers
INTRODUCTION: The majority of breast cancers that occur in BRCA1 mutation carriers (BRCA1 carriers) are estrogen receptor-negative (ER-). Therefore, it has been suggested that ER negativity is intrinsic to BRCA1 cancers and reflects the cell of origin of these tumors. However, approximately 20% of b...
Autores principales: | Tung, Nadine, Miron, Alexander, Schnitt, Stuart J, Gautam, Shiva, Fetten, Katharina, Kaplan, Jennifer, Yassin, Yosuf, Buraimoh, Ayodele, Kim, Ji-Young, Szász, Attila M, Tian, Ruiyang, Wang, Zhigang C, Collins, Laura C, Brock, Jane, Krag, Karen, Legare, Robert D, Sgroi, Dennis, Ryan, Paula D, Silver, Daniel P, Garber, Judy E, Richardson, Andrea L |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046438/ https://www.ncbi.nlm.nih.gov/pubmed/21080930 http://dx.doi.org/10.1186/bcr2776 |
Ejemplares similares
-
Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features
por: Tung, Nadine, et al.
Publicado: (2010) -
Patterns of recurrence and metastasis in BRCA1/BRCA2‐associated breast cancers
por: Song, Yun, et al.
Publicado: (2019) -
BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
por: Cline, Melissa S., et al.
Publicado: (2018) -
Predominance of BRCA2 Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with BRCA1 or BRCA2 Mutation
por: Pujol, Pascal, et al.
Publicado: (2022) -
BRCA1/2 testing: therapeutic implications for breast cancer management
por: Tung, Nadine M., et al.
Publicado: (2018)